Thematic

Genomics & Biotech Innovation ETFs

Pre-profit biotech with binary outcomes on trial data. These funds are extremely rate-sensitive and have drawn down 70%+ in bad cycles, so position size matters more than fund selection.

Theme performance

Equal-weighted across every fund in this objective

1Y: +16.6%
5Y ann.: -6.7%
10Y ann.: —
All-time ann.: —

Sort5 funds

IBB

iShares Biotechnology ETF

iShares

Large-cap biotech. Higher volatility, no pharma or device diversification.

Fee: 0.45%
AUM: $6.8B
Yield: 0.2%

1Y: +14.6%
5Y ann.: +2.4%
10Y ann.: —
Max ann.: —

XBI

SPDR S&P Biotech ETF

SPDR

Equal-weighted biotech dominated by small-cap clinical-stage names. Very high beta.

Fee: 0.35%
AUM: $6.2B
Yield: 0.0%

1Y: +19.4%
5Y ann.: -3.6%
10Y ann.: —
Max ann.: —

ARKG

ARK Genomic Revolution ETF

ARK

Actively managed, concentrated bets on gene editing, molecular diagnostics and agricultural biology.

Fee: 0.75%
AUM: $1.3B
Yield: 0.0%

1Y: +18.4%
5Y ann.: -14.1%
10Y ann.: —
Max ann.: —

IDNA

iShares Genomics Immunology and Healthcare ETF

iShares

Index-based genomics with a cap on single-name weight, so far less concentrated than ARKG.

Fee: 0.47%
AUM: $200M
Yield: 0.2%

1Y: +14.6%
5Y ann.: -6.9%
10Y ann.: —
Max ann.: —

GNOM

Global X Genomics & Biotechnology ETF

Global X

Equal-ish weighted genomics basket spanning sequencing, bioinformatics and cell therapy.

Fee: 0.50%
AUM: $100M
Yield: 0.1%

1Y: +16.1%
5Y ann.: -11.4%
10Y ann.: —
Max ann.: —